上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2024 , Vol. 44 >Issue 10: 1307 - 1315

DOI: https://doi.org/10.3969/j.issn.1674-8115.2024.10.013

综述

肾细胞癌舒尼替尼耐药性的机制及治疗研究进展

  • 陈子旋 ,
  • 刘敏
展开
  • 上海交通大学医学院附属同仁医院泌尿外科，上海 200336
陈子旋（1999—），男，傣族，硕士生；电子信箱：czixuan2023@126.com。
刘　敏，电子信箱：lm4104@shtrhospital.com。

收稿日期: 2024-03-20

  录用日期: 2024-06-04

  网络出版日期: 2024-10-28

基金资助

国家自然科学基金(82172809);上海市长宁区科委项目(CNKW2020Y11)

收起

Progress in mechanisms and treatment of sunitinib resistance in renal cell carcinoma

  • Zixuan CHEN ,
  • Min LIU
Expand
  • Department of Urology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China
LIU Min, E-mail: lm4104@shtrhospital.com.

Received date: 2024-03-20

  Accepted date: 2024-06-04

  Online published: 2024-10-28

Supported by

National Natural Science Foundation of China(82172809);Shanghai Changning District Science and Technology Commission Project(CNKW2020Y11)

Fold

摘要

肾细胞癌（renal cell carcinoma，RCC）起源于肾小管上皮细胞，是最常见的肾癌类型，也是死亡率最高的泌尿系统肿瘤。近半个世纪以来，RCC的发病率和死亡率持续上升，给人类健康带来了极大的威胁。尽管手术治疗为大多数 RCC 患者提供了治愈的可能，但肿瘤的复发或转移导致传统治疗方案无法达到理想的效果。因此，受体酪氨酸激酶抑制剂和免疫检查点抑制剂等靶向药物的出现，给RCC的治疗带来了新的希望。靶向治疗成为治疗晚期RCC的主要方式。舒尼替尼是一种受体酪氨酸激酶抑制剂，其通过抑制表皮生长因子受体、血小板衍生生长因子受体、血管内皮生长因子受体等多种受体酪氨酸激酶的活性，抑制肿瘤的血管生成和细胞增殖，最终有效控制肿瘤进展，在RCC的治疗中发挥着关键作用。然而，相当多的RCC患者在使用舒尼替尼治疗后的15个月内对其产生耐药性，给RCC的治疗带来了新的挑战。该文总结了RCC舒尼替尼耐药性的发生机制，归纳了RCC舒尼替尼耐药性的治疗策略，以期为克服RCC对舒尼替尼的耐药，给晚期RCC患者制定更有效的治疗方案提供思路。

关键词： 舒尼替尼; 肾细胞癌; 耐药; 代谢重编程; 治疗策略

本文引用格式

陈子旋 , 刘敏 . 肾细胞癌舒尼替尼耐药性的机制及治疗研究进展[J]. 上海交通大学学报（医学版）, 2024 , 44(10) : 1307 -1315 . DOI: 10.3969/j.issn.1674-8115.2024.10.013

Abstract

Renal cell carcinoma (RCC) originates from the epithelial cells of renal tubules and is the most common type of renal cancer, as well as the urological tumor with the highest mortality rate. Over the past half-century, the morbidity and mortality of RCC have been increasing, posing a significant threat to human health. Although surgical treatment offers the possibility of a cure for most RCC patients, tumor recurrence or metastasis leads to the failure of traditional treatment options to achieve the desired results. The advent of targeted drugs, such as receptor tyrosine kinase inhibitors and immune checkpoint inhibitors, has brought new hope for the treatment of RCC. Targeted therapy has become the mainstay of treatment for advanced RCC. Sunitinib is a receptor tyrosine kinase inhibitor that plays a pivotal role in the treatment of RCC. It inhibits the activity of various receptor tyrosine kinases, including epidermal growth factor receptor, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor. This, in turn, inhibits tumor angiogenesis and cellular proliferation, effectively controlling tumor progression. However, a considerable number of RCC patients develop resistance to sunitinib within 15 months of initiating treatment, presenting new challenges for the treatment of RCC. Therefore, this paper summarizes the mechanism of sunitinib resistance in RCC and reviews the treatment of sunitinib resistance in RCC, in order to provide ideas for overcoming the resistance of RCC to sunitinib, and developing a more effective treatment plan for patients with advanced RCC.

Key words： sunitinib; renal cell carcinoma; resistance; metabolic reprogramming; treatment strategy

参考文献

1 RAHIB L, WEHNER M R, MATRISIAN L M, et al. Estimated projection of US cancer incidence and death to 2040[J]. JAMA Netw Open, 2021, 4(4): e214708.
2 SEMENESCU L E, KAMEL A, CIUBOTARU V, et al. An overview of systemic targeted therapy in renal cell carcinoma, with a focus on metastatic renal cell carcinoma and brain metastases[J]. Curr Issues Mol Biol, 2023, 45(9): 7680-7704.
3 JIN J, XIE Y H, ZHANG J S, et al. Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers[J]. Drug Resist Updat, 2023, 67: 100929.
4 SHARMA R, KADIFE E, MYERS M, et al. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma[J]. J Exp Clin Cancer Res, 2021, 40(1): 186.
5 BI K, HE M X, BAKOUNY Z, et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma[J]. Cancer Cell, 2021, 39(5): 649-661.e5.
6 MIKAMI S, MIZUNO R, KOSAKA T, et al. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma[J]. Pathol Int, 2020, 70(10): 712-723.
7 何凯桐, 周阳, 王明珠, 等. 受体酪氨酸激酶AXL在肿瘤生物学中的作用研究进展[J]. 现代肿瘤医学, 2024, 32(1): 167-171.
7 HE K T, ZHOU Y, WANG M Z, et al. Research progress on the role of receptor tyrosine kinase AXL in tumor biology [J]. Journal of Modern Oncology, 2024, 32(1): 167-171.
8 CHEN S J, QIAN S B, ZHANG L, et al. Tumor-associated macrophages promote migration and invasion via modulating IL-6/STAT3 signaling in renal cell carcinoma[J]. Int Immunopharmacol, 2022, 111: 109139.
9 WANG Y, WANG Y Y, QIN Z Y, et al. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer[J]. Expert Opin Drug Metab Toxicol, 2021, 17(3): 291-306.
10 LIU S Z, YAO S J, YANG H, et al. Autophagy: regulator of cell death[J]. Cell Death Dis, 2023, 14(10): 648.
11 LI X H, HE S K, MA B Y. Autophagy and autophagy-related proteins in cancer[J]. Mol Cancer, 2020, 19(1): 12.
12 WONG J J W, BERSTAD M B, FREMSTEDAL A S V, et al. Photochemically-induced release of lysosomal sequestered sunitinib: obstacles for therapeutic efficacy[J]. Cancers, 2020, 12(2): 417.
13 NAGASE K, AKUTAGAWA T, RIKITAKE-YAMAMOTO M, et al. Cellular and physical microenvironments regulate the aggressiveness and sunitinib chemosensitivity of clear cell renal cell carcinoma[J]. J Pathol, 2021, 254(1): 46-56.
14 AMBROSETTI D, COUTTS M, PAOLI C, et al. Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy[J]. BJU Int, 2022, 129(1): 80-92.
15 XU C F, JOHNSON T, GARCIA-DONAS J, et al. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma[J]. Br J Cancer, 2015, 112(7): 1190-1198.
16 彭恬, 徐雷鸣. 表观遗传修饰与环状RNA在结直肠癌中相互作用的研究进展[J]. 上海交通大学学报(医学版), 2023, 43(2): 237-243.
16 PENG T, XU L M. Crosstalk between epigenetic modification and circRNA in colorectal cancer: recent advances [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(2): 237-243.
17 ZHAO T L, ZHOU Y L, WANG Q Y, et al. QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis[J]. Int J Oncol, 2021, 59(1): 48.
18 CHEN Y L, LU Z Y, QI C, et al. N6-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma[J]. Mol Cancer, 2022, 21(1): 111.
19 WANG J F, WANG C, XU P, et al. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma[J]. Theranostics, 2021, 11(11): 5387-5403.
20 LIU Y Q, ZHANG H, FANG Y, et al. Non-coding RNAs in renal cell carcinoma: implications for drug resistance[J]. Biomedecine Pharmacother, 2023, 164: 115001.
21 ZHU H Y, WANG X, LU S H, et al. Metabolic reprogramming of clear cell renal cell carcinoma[J]. Front Endocrinol, 2023, 14: 1195500.
22 SATO T, KAWASAKI Y, MAEKAWA M, et al. Metabolomic analysis to elucidate mechanisms of sunitinib resistance in renal cell carcinoma[J]. Metabolites, 2020, 11(1): 1.
23 LIBERTI M V, LOCASALE J W. The Warburg effect: how does it benefit cancer cells?[J]. Trends Biochem Sci, 2016, 41(3): 211-218.
24 CHEN W F, HILL H, CHRISTIE A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist[J]. Nature, 2016, 539(7627): 112-117.
25 NAITO S, MAKHOV P, ASTSATUROV I, et al. LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma[J]. Br J Cancer, 2017, 116(9): 1203-1207.
26 GARCIA J, HURWITZ H I, SANDLER A B, et al. Bevacizumab (Avastin?) in cancer treatment: a review of 15years of clinical experience and future outlook[J]. Cancer Treat Rev, 2020, 86: 102017.
27 ZOU Z L, TAO T, LI H M, et al. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges[J]. Cell Biosci, 2020, 10: 31.
28 MAKHOV P B, GOLOVINE K, KUTIKOV A, et al. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells[J]. Mol Cancer Ther, 2012, 11(7): 1510-1517.
29 SAHARINEN P, EKLUND L, ALITALO K. Therapeutic targeting of the angiopoietin-TIE pathway[J]. Nat Rev Drug Discov, 2017, 16(9): 635-661.
30 MOOI J, CHIONH F, SAVAS P, et al. Dual antiangiogenesis agents bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer: results of a phase II study[J]. Clin Cancer Res, 2021, 27(8): 2159-2167.
31 ATKINS M B, GRAVIS G, DROSIK K, et al. Trebananib (AMG 386) in combination with sunitinib in patients with metastatic renal cell cancer: an open-label, multicenter, phase II study[J]. J Clin Oncol, 2015, 33(30): 3431-3438.
32 SAMMARCO E, MANFREDI F, NUZZO A, et al. Immune checkpoint inhibitor rechallenge in renal cell carcinoma: current evidence and future directions[J]. Cancers, 2023, 15(12): 3172.
33 MOTZER R J, POWLES T, BUROTTO M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2022, 23(7): 888-898.
34 BAJALIA E M, AZZOUZ F B, CHISM D A, et al. Phytochemicals for the prevention and treatment of renal cell carcinoma: preclinical and clinical evidence and molecular mechanisms[J]. Cancers, 2022, 14(13): 3278.
35 ASHAQ A, MAQBOOL M F, MARYAM A, et al. Hispidulin: a novel natural compound with therapeutic potential against human cancers[J]. Phytother Res, 2021, 35(2): 771-789.
36 PORTA C, PROCOPIO G, CARTENì G, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases[J]. BJU Int, 2011, 108(8 Pt 2): E250-E257.
37 张楠. 口服抗癌疫苗正在走向现实[N]. 中国科学报, 2022-05-16(3).
37 ZHANG N. Oral cancer vaccines are becoming a reality[N]. China Science Daily, 2022-05-16(3).
38 DEBENEDETTE M, GAMBLE A, NORRIS M, et al. A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma[J]. Hum Vaccin Immunother, 2023, 19(2): 2220629.
39 CHEN R H, XIAO Z W, YAN X Q, et al. Tumor cell-secreted ISG15 promotes tumor cell migration and immune suppression by inducing the macrophage M2-like phenotype[J]. Front Immunol, 2020, 11: 594775.
40 NGUYEN H M, OLADEJO M, PAULISHAK W, et al. A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma[J]. Cancer Immunol Immunother, 2023, 72(9): 2889-2903.
41 PUROHIT K, REDDY N, SUNNA A. Exploring the potential of bioactive peptides: from natural sources to therapeutics[J]. Int J Mol Sci, 2024, 25(3): 1391.
42 KUMAR V, BARWAL A, SHARMA N, et al. Therapeutic proteins: developments, progress, challenges, and future perspectives[J]. 3 Biotech, 2024, 14(4): 112.
43 ZHANG L, JIN G Z, LI D. Tat-hspb1 suppresses clear cell renal cell carcinoma (ccRCC) growth via lysosomal membrane permeabilization[J]. Cancers (Basel), 2022, 14(22): 5710.
44 LI X, LIU M H, LIU H Y, et al. Tumor metabolic reprogramming in lung cancer progression[J]. Oncol Lett, 2022, 24(2): 287.
45 WANG R L, YAN Q, LIU X, et al. Unraveling lipid metabolism reprogramming for overcoming drug resistance in melanoma[J]. Biochem Pharmacol, 2024, 223: 116122.
46 JONASCH E, WALKER C L, RATHMELL W K. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality[J]. Nat Rev Nephrol, 2021, 17(4): 245-261.
47 CHOUEIRI T K, BAUER T M, PAPADOPOULOS K P, et al. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis[J]. Nat Med, 2021, 27(5): 802-805.
48 TAN S K, HOUGEN H Y, MERCHAN J R, et al. Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets[J]. Nat Rev Urol, 2023, 20(1): 48-60.
49 ZHOU L J, LUO Y B, LIU Y N, et al. Fatty acid oxidation mediated by malonyl-CoA decarboxylase represses renal cell carcinoma progression[J]. Cancer Res, 2023, 83(23): 3920-3939.
50 BENSAAD K, FAVARO E, LEWIS C A, et al. Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation[J]. Cell Rep, 2014, 9(1): 349-365.
51 MURANAKA H, AKINSOLA R, BILLET S, et al. Glutamine supplementation as an anticancer strategy: a potential therapeutic alternative to the convention[J]. Cancers, 2024, 16(5): 1057.
52 MOROZUMI K, KAWASAKI Y, SATO T, et al. Elucidation and regulation of tyrosine kinase inhibitor resistance in renal cell carcinoma cells from the perspective of glutamine metabolism[J]. Metabolites, 2024, 14(3): 170.
53 SCHULTE M L, FU A, ZHAO P, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models[J]. Nat Med, 2018, 24(2): 194-202.
54 LOI S, SETTLEMAN J, JOYCE J A, et al. The next big questions in cancer research[J]. Cell, 2023, 186(8): 1523-1527.
Options
文章导航

/

〈 〉